Form 4: Corcept Director Exercises Options, Transfers Shares

Corcept Therapeutics director James N. Wilson exercised stock options and transferred a significant block of shares to a family trust.

Summary

• Director James N. Wilson exercised 100,000 stock options for Corcept Therapeutics common stock at an exercise price of $3.88 per share on February 24, 2026.
• 10,636 shares were withheld at a price of $36.48 per share to satisfy the exercise price arising from a net (cashless) exercise of stock options.
• 89,364 shares were transferred without consideration to the James N. Wilson and Pamela D. Wilson Trust.
• Following these transactions, direct beneficial ownership of common stock by Mr. Wilson is 0 shares.
• Indirect beneficial ownership includes 1,134,532 shares through the James N. Wilson and Pamela D. Wilson Trust, 901,067 shares through James and Pamela Wilson Family Partners, 200,000 shares through James N. Wilson 2025 Grantor Retained Annuity Trust, and 200,000 shares through Pamela D. Wilson 2025 Grantor Retained Annuity Trust.
• The exercised stock options were fully exercisable and were set to expire on February 26, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a largely neutral event, reflecting a director's personal financial planning rather than a direct signal about the company's immediate prospects. The exercise of deeply in-the-money options is a positive for the director, but the subsequent transfer to a trust is a common estate planning move.

Positives

• The director exercised stock options with a strike price of $3.88, significantly below the $36.48 price at which shares were withheld for tax purposes, indicating a substantial in-the-money value.
• The exercise of options before their expiration demonstrates the director's realization of value from their equity compensation.

Negatives

• The director's direct beneficial ownership of common stock is now 0 shares, although significant indirect ownership remains.
• A substantial number of shares (89,364) were transferred without consideration to a family trust, which is a personal financial strategy rather than a direct investment decision.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly option exercises followed by transfers to trusts, are common for long-serving directors for estate planning and tax optimization purposes. These actions typically do not reflect a change in the company's operational outlook but rather a personal financial strategy.

Comparison to Industry Standards

• StockSavvy.ai observes that the exercise of deeply in-the-money options, such as those with a $3.88 strike price compared to a $36.48 market price, is a standard practice for executives and directors in the biotechnology and pharmaceutical sectors as options approach expiration.
• Similar transactions are seen across companies like Amgen (AMGN) or Gilead Sciences (GILD) where long-held options are exercised and then managed through trusts for wealth preservation.

Related Party Transactions

• Transfer of 89,364 shares without consideration to the James N. Wilson and Pamela D. Wilson Trust.
• Indirect beneficial ownership through James N. Wilson and Pamela D. Wilson Trust, James and Pamela Wilson Family Partners, James N. Wilson 2025 Grantor Retained Annuity Trust, and Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

Stakeholder Impact

• Shareholders: The transactions represent a director managing personal equity holdings, which is a routine event and does not directly impact company operations or strategy. The director maintains significant indirect ownership, aligning interests with shareholders.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the exercise of expiring stock options and subsequent transfer of shares to a family trust for estate planning purposes. It does not provide new information regarding Corcept Therapeutics' operational performance, strategic direction, or financial health that would warrant a change in investment thesis. The director maintains substantial indirect beneficial ownership, suggesting continued alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Options, Beneficial Ownership, Director Transactions, Equity Compensation, Trust Transfer